Eledon Pharmaceuticals, Inc.
ELDN
$2.62
$0.0451.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.47% | 48.90% | 46.65% | 19.90% | 15.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.40% | 81.65% | 64.13% | 31.65% | 11.41% |
| Operating Income | -87.40% | -81.65% | -64.13% | -31.65% | -11.41% |
| Income Before Tax | 113.89% | 85.61% | 69.32% | 85.04% | 25.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 113.49% | 85.28% | 68.95% | 85.04% | 25.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 113.49% | 85.28% | 68.95% | 85.04% | 25.34% |
| EBIT | -87.40% | -81.65% | -64.13% | -31.65% | -11.41% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 106.93% | 85.68% | 70.99% | 77.20% | 61.74% |
| Normalized Basic EPS | 119.46% | 93.88% | 79.26% | 69.58% | 35.17% |
| EPS Diluted | 64.10% | 57.63% | 42.75% | 59.98% | 61.74% |
| Normalized Diluted EPS | 116.50% | 91.94% | 77.30% | 67.49% | 35.17% |
| Average Basic Shares Outstanding | 108.71% | 111.56% | 97.41% | 86.88% | 97.93% |
| Average Diluted Shares Outstanding | 111.38% | 114.66% | 101.00% | 91.16% | 97.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |